About US
Contact us
-
European Medicines Agency to start review of Gilead’s cancer medicine ZydeligThe European Commission has requested the European Medicines Agency (EMA) to start a review of Gilead Science's cancer medicine Zydelig (idelalisib), following concerns over serious adverse events in2016/3/16
-
India’s Lupin completes $880m acquisition of US firm GavisIndian drugmaker Lupin has completed the acquisition of US-based Gavis Pharmaceuticals and Novel Laboratories (Gavis) in a previously announced deal worth $880m. The move comes on the heels of Lupin2016/3/16
-
Pfizer wins stay from Indian court after regulator bans popular cough syrupsWestern drugmakers often complain about what sometimes seems like the capricious nature of Indian drug regulation. Now Pfizer ($PFE) has asked an Indian court to get involved after a regulator include2016/3/15
-
EMA puts Gilead's Zydelig under the lens after deaths crop up in trialsGilead's ($GILD)Zydelighas been working to carve out a place for itself as it battles other blood cancer heavyweights. But now, European regulators are undertaking a safety review of the med that coul2016/3/15
-
EU revokes one of the patents on Biogen blockbuster TecfideraBiogen ($BIIB) has faced a number of challenges to its top-selling drug, multiple sclerosis medTecfidera, in the few years since it has been on the market. Now it faces a new one in Europe in the alwa2016/3/14
-
Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJPlenty of industry watchers didn't expect to see embattled Valeant ($VRX) CEO J. Michael Pearson return to the helm after a two-month bout with severe pneumonia. And as it turns out, he almost didn't.2016/3/14
-
Sanofi Pasteur and MSD to terminate vaccines JV in EuropeSanofi Pasteur and MSD, known as Merck in the US and Canada, are planning to terminate their joint venture (JV) that is involved in the development and commercialisation of vaccines in Europe. The JV2016/3/11
-
FDA approves Roche’s Gazyva to treat follicular lymphomaThe US Food and Drug Administration (FDA) has granted approval for Roche's approved Gazyva (obinutuzumab) plus bendamustine chemotherapy, followed by Gazyva alone as a new treatment for people with fo2016/3/11
-
Bristol-Myers scraps doc payments in China after last fall's FCPA settlementBristol-Myers Squibb ($BMY) is cracking down on its promotions inChina. According to multiple reports on news sites and social media, the company will stop paying speaker fees to doctors, curtail spen2016/3/10
-
AstraZeneca's Faslodex receives FDA approval for new indicationAstraZeneca has received approval from the US Food and Drug Administration (FDA) for a new indication of its Faslodex (fulvestrant) to treat women with hormone receptor-positive (HR+), human epidermal2016/3/10